| Citation: |
YANG Zhi, TONG Qiaoyun, WANG Zhenhua, LIU Wei. Associations of estimated glucose disposal rate with liver steatosis and fibrosis[J]. Journal of Clinical Medicine in Practice, 2025, 29(7): 50-57. DOI: 10.7619/jcmp.20250282
|
To investigate the association of estimated glucose disposal rate (eGDR) with metabolic dysfunction-associated liver steatosis and fibrosis, and to analyze the difference of the association in different population.
A total of 10, 549 participants from 2017 to 2020 in National Health and Nutrition Examination Survey (NHANES) database who underwent vibration-controlled transient elastography (VCTE) were included. eGDR was calculated based on waist circumference, hypertension, and glycated hemoglobin (HbA1c). The controlled attenuation parameter (CAP) ≥ 248 dB/m was used as diagnostic criterion for liver steatosis, and liver stiffness measurement (LSM) ≥ 8.2 kPa was used as criterion for liver fibrosis. Multivariable Logistic regression analysis was conducted to assess the relationship between eGDR and liver steatosis and fibrosis, with subgroup analysis and interaction tests performed.
After adjusting for confounding factors, eGDR level was significantly negatively associated with the risks of both liver steatosis and fibrosis. The participants were divided into tertiles based on eGDR levels (Q1, Q2, Q3). Compared with the Q1 group, the risk ratios for liver steatosis in the Q2 and Q3 groups were 0.485 (95%CI, 0.394 to 0.597) and 0.286 (95%CI, 0.239 to 0.343), respectively(P < 0.001); the risk ratios for liver fibrosis were 0.457 (95%CI, 0.363 to 0.576) and 0.162 (95%CI, 0.100 to 0.263), respectively (P < 0.001). Subgroup analysis showed that the negative association between eGDR and liver steatosis differed among populations of different ages and smoking statuses, with statistically significant differences in interaction tests (P for interaction < 0.001); similarly, the negative association between eGDR and liver fibrosis differed among populations with different levels of physical activity, with statistically significant differences in interaction tests (P for interaction < 0.001). The associations of eGDR levels with liver steatosis and fibrosis remained stable (P for interaction>0.05).
eGDR levels are closely associated with the risks of liver steatosis and fibrosis and can serve as an effective indicator for assessing liver metabolic abnormalities. This finding provides new insights into early screening, risk stratification, and prognosis assessment for liver steatosis and fibrosis.
| [1] |
PAN J, WU F, CHEN M, et al. Prevalence of nafld, mafld, and masld: nhanes 1999-2018[J]. Diabetes Metab, 2024, 50(6): 101562. doi: 10.1016/j.diabet.2024.101562
|
| [2] |
PAROLA M, PINZANI M. Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies[J]. Mol Aspects Med, 2024, 95: 101231. doi: 10.1016/j.mam.2023.101231
|
| [3] |
WELLS R G. Liver fibrosis: our evolving understanding[J]. Clin Liver Dis: Hoboken, 2024, 23(1): e0243.
|
| [4] |
ZHANG W, SONG W J, CHEN W, et al. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease[J]. Eur J Gastroenterol Hepatol, 2024, 36(6): 802-810. doi: 10.1097/MEG.0000000000002767
|
| [5] |
FABRIS L, CAMPELLO E, CADAMURO M, et al. The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit[J]. Biochim Biophys Acta BBA Mol Basis Dis, 2024, 1870(3): 166763. doi: 10.1016/j.bbadis.2023.166763
|
| [6] |
沈颖筱, 施惠海, 罗家乐, 等. 非酒精性脂肪性肝病肝纤维化风险预测模型的应用与进展[J]. 实用临床医药杂志, 2023, 27(9): 131-136, 142. doi: 10.7619/jcmp.20222652
|
| [7] |
ZHANG Z, ZHAO L, LU Y, et al. Insulin resistance assessed by estimated glucose disposal rate and risk of incident cardiovascular diseases among individuals without diabetes: findings from a nationwide, population based, prospective cohort study[J]. Cardiovasc Diabetol, 2024, 23(1): 194. doi: 10.1186/s12933-024-02256-5
|
| [8] |
YI J, QU C, LI X, et al. Insulin resistance assessed by estimated glucose disposal rate and risk of atherosclerotic cardiovascular diseases incidence: the multi-ethnic study of atherosclerosis[J]. Cardiovasc Diabetol, 2024, 23(1): 349. doi: 10.1186/s12933-024-02437-2
|
| [9] |
JUNG I, KOO D J, LEE W Y. Insulin resistance, non-alcoholic fatty liver disease and type 2 diabetes mellitus: clinical and experimental perspective[J]. Diabetes Metab J, 2024, 48(3): 327-339. doi: 10.4093/dmj.2023.0350
|
| [10] |
JOHNSON C L, DOHRMANN S M, BURT V L, et al. National health and nutrition examination survey: sample design, 2011-2014[J]. Vital Health Stat 2, 2014(162): 1-33.
|
| [11] |
WANG S, ZHANG Q, QIN B. Association between remnant cholesterol and insulin resistance levels in patients with metabolic-associated fatty liver disease[J]. Sci Rep, 2024, 14(1): 4596. doi: 10.1038/s41598-024-55282-4
|
| [12] |
KARLAS T, PETROFF D, SASSO M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis[J]. J Hepatol, 2017, 66(5): 1022-1030. doi: 10.1016/j.jhep.2016.12.022
|
| [13] |
MIKOLASEVIC I, DOMISLOVIC V, KLAPAN M, et al. Accuracy of controlled attenuation parameter and liver stiffness measurement in patients with non-alcoholic fatty liver disease[J]. Ultrasound Med Biol, 2021, 47(3): 428-437. doi: 10.1016/j.ultrasmedbio.2020.11.015
|
| [14] |
KARAASLAN H, INAN H, TURKMEN A T, et al. Comparison of triglyceride-glucose index and anthropometric obesity indices in predicting severe grades of hepatic steatosis in nonalcoholic fatty liver disease among non-diabetic obese individuals[J]. Hepatol Forum, 2024, 5(3): 113-119.
|
| [15] |
SHI J, CHEN J, ZHANG Z, et al. Multi-dimensional comparison of abdominal obesity indices and insulin resistance indicators for assessing NAFLD[J]. BMC Public Health, 2024, 24(1): 2161. doi: 10.1186/s12889-024-19657-6
|
| [16] |
SONG J, MA R, YIN L. Associations between estimated glucose disposal rate and arterial stiffness and mortality among US adults with non-alcoholic fatty liver disease[J]. Front Endocrinol: Lausanne, 2024, 15: 1398265. doi: 10.3389/fendo.2024.1398265
|
| [17] |
CHEN Y, ZHAO X. The mediating role of insulin resistance in the association between inflammatory score and MAFLD: NHANES 2017-2018[J]. Immun Inflamm Dis, 2024, 12(10): e70035. doi: 10.1002/iid3.70035
|
| [18] |
TAUIL R B, GOLONO P T, DE LIMA E P, et al. Metabolic-associated fatty liver disease: the influence of oxidative stress, inflammation, mitochondrial dysfunctions, and the role of polyphenols[J]. Pharmaceuticals: Basel, 2024, 17(10): 1354. doi: 10.3390/ph17101354
|
| [19] |
ZHAO Y, ZHOU Y, WANG D, et al. Mitochondrial dysfunction in metabolic dysfunction fatty liver disease (MAFLD)[J]. Int J Mol Sci, 2023, 24(24): 17514. doi: 10.3390/ijms242417514
|
| [20] |
POPA S G, SIMION A M, SOARE M, et al. Insulin resistance and hepatic steatosis in type 1 diabetes mellitus and their association with diabetic chronic complications[J]. Minerva Endocrinol: Torino, 2023, 48(1): 27-34.
|
| [21] |
FAN X D, SONG Y F, ZHAO J J. Evolving liver disease insights from NAFLD to MASLD[J]. Trends Endocrinol Metab, 2024, 35(8): 683-686. doi: 10.1016/j.tem.2024.02.012
|
| [22] |
CHAN W K, WONG V W, ADAMS L A, et al. MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD[J]. Hepatol Int, 2024, 18(2): 909-921.
|
| [23] |
VIEIRA-LARA M A, DOMMERHOLT M B, ZHANG W X, et al. Age-related susceptibility to insulin resistance arises from a combination of CPT1B decline and lipid overload[J]. BMC Biol, 2021, 19(1): 154. doi: 10.1186/s12915-021-01082-5
|
| [24] |
BAJAJ M. Nicotine and insulin resistance: when the smoke clears[J]. Diabetes, 2012, 61(12): 3078-3080. doi: 10.2337/db12-1100
|
| [25] |
VAN DER VELDE J H P M, BOONE S C, WINTERS-VAN EEKELEN E, et al. Timing of physical activity in relation to liver fat content and insulin resistance[J]. Diabetologia, 2023, 66(3): 461-471. doi: 10.1007/s00125-022-05813-3
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: